364TiPAnti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97. (23rd October 2018) - Decker, T